Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study.

Although this study did not observe significant differences in OS or PFS between the PD-L1 CPS ≥1 and CPS <1 groups, the survival curves of the CPS ≥1 group showed a trend toward better outcomes than did those of the CPS <1 group.

also in 53,322 other papers